AbbVie-Roche leukemia pairing gets a vexing thumbs-down from NICE

Nice Recommendations

1.1  Venetoclax with rituximab is not recommended, within its anticipated marketing authorisation, for treating relapsed or refractory chronic lymphocytic leukaemia in adults.

1.2  This recommendation is not intended to affect treatment with venetoclax with rituximab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Read full briefing